Major Depressive Disorder
1,720
199
247
1,056
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
426 trials with published results (25%)
Research Maturity
1056 completed trials (61% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
5.9%
102 terminated out of 1720 trials
91.2%
+4.7% vs benchmark
26%
443 trials in Phase 3/4
40%
426 of 1056 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1056 completed trials
Clinical Trials (1720)
Neuromodulation of Different Doses to Treat TRD Guided by pBFS Technique
Imagery Rescripting as Treatment for Depression
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
Aβ Dynamics in LLMD
Rapid Antidepressant Dynamics in Acute Neuromodulation Treatments
Mindfulness Engaged Neurostimulation for Depression (MEND II)
Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer
Defining Neurobiological Links Between Substance Use and Mental Illness
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Mindful Self-compassion for Anxiety and Depression: Impact of Delivery Method
RESISTance Exercise for Depression Trial
PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder
Regulation of Affect and Physiology in Depression
Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
Impact of Transcutaneous Vagal Nerve Stimulation on Stress Response in Major Depression
Maintenance rTMS for Depression (Maitr-De)
Neutralizing Interleukin (IL)-6